HRGN — what changed in the latest 10-Q
A section-by-section comparison of HRGN's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +22 | −15 | ~3 | 25 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
Product revenue was $414,000 and $317,000 for the three months ended June 30, 2026 and 2025, respectively. The $97,000 increase, representing a 31% growth, was driven by expanded distribution and new product launches within our Consumer Health segment, including CoQ-10 and sleep aid gummies, alongsi…
Cost of sales was $391,000 and $302,000 for the three months ended June 30, 2026 and 2025, respectively. The increase reflects scaling of operations to match higher sales.
Research and development expense increased approximately 36%, to approximately $0.9 million for the three months ended June 30, 2026 as compared to approximately $0.7 million for the three months ended June 30, 2025. This increase was primarily attributable to higher costs associated with clinical a…
Selling and marketing expense was approximately $16,000 for the three months ended June 30, 2026. We did not incur selling and marketing expense during the three months ended June 30, 2025. This increase included advertising and promotional costs.
General and administrative expense decreased approximately 35%, to approximately $0.8 million for the three months ended June 30, 2026 as compared to approximately $1.2 million for the three months ended June 30, 2025. This decrease was primarily attributable to lower share-based compensation expens…
Text removed vs the prior filing · source: 10-Q · 2026-05-13
Comparison of the three months ended March 31, 2026 and 2025
Product revenue was $226,000 and $45,000 for the three months ended March 31, 2026 and 2025, respectively. The $181,000 increase, representing a 402% growth, was driven by expanded distribution and new product launches within our Consumer Health segment, including CoQ-10 and sleep aid gummies, along…
Cost of sales was $206,000 and $33,000 for the three months ended March 31, 2026 and 2025, respectively. The increase reflects scaling of operations to match higher sales.
Research and development expense decreased approximately 6%, to approximately $0.56 million for the three months ended March 31, 2026 as compared to approximately $0.60 million for the three months ended March 31, 2025. This decrease was primarily reflecting lower preclinical spend.
Selling and marketing expense increased approximately 80%, to approximately $18,000 for the three months ended March 31, 2026 as compared to approximately $10,000 the three months ended March 31, 2025 This increase included advertising and promotional costs.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice